Plant Name: Paulownia tomentosa
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.779E-09 | 1.937E-05 | CYP19A1, CYP1A1, CYP1B1, CYP2C19, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 6.926E-09 | 3.952E-05 | CYP19A1, CYP1A1, CYP1B1, CYP2C19, CYP3A4, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.332E-08 | 4.144E-05 | CYP19A1, CYP1A1, CYP1B1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.760E-07 | 2.395E-04 | CYP1A1, CYP1B1, CYP2C19 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 2.026E-07 | 2.595E-04 | BCHE, CYP1A1, CYP1B1, CYP2C19, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 6.647E-07 | 6.597E-04 | CA12, CA4, CA7 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.092E-06 | 8.872E-04 | CYP19A1, CYP1A1, CYP1B1, CYP2C19, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0003990; acetylcholinesterase activity | 1.356E-06 | 1.055E-03 | ACHE, BCHE |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.934E-06 | 1.276E-03 | CYP1A1, CYP1B1, CYP2C19 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 4.066E-06 | 2.459E-03 | CYP1A1, CYP3A4 |
| BP | GO:0032501; multicellular organismal process | GO:0010575; positive regulation of vascular endothelial growth factor production | 4.234E-06 | 2.492E-03 | CYP1B1, HIF1A, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 5.557E-06 | 2.931E-03 | CYP19A1, CYP1A1, CYP1B1, CYP2C19, CYP3A4, GAA, HSD17B1, PTGS2 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 5.944E-06 | 3.010E-03 | CA7, HIF1A, MAPK1, NPC1, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.026E-05 | 4.469E-03 | CA12, CA4, CA7 |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.353E-05 | 5.667E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0032787; monocarboxylic acid metabolic process | 1.589E-05 | 6.291E-03 | CYP1A1, CYP1B1, CYP2C19, HIF1A, NPC1, PTGS2 |
| BP | GO:0007610; behavior | GO:0007612; learning | 1.876E-05 | 6.982E-03 | BCHE, HIF1A, KIT, PTGS2 |
| BP | GO:0032501; multicellular organismal process | GO:0043536; positive regulation of blood vessel endothelial cell migration | 1.892E-05 | 6.982E-03 | HIF1A, PRKCA, PTGS2 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.892E-05 | 6.982E-03 | CA12, CA4, CA7 |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 2.028E-05 | 7.124E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.028E-05 | 7.124E-03 | CYP2C19, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0017144; drug metabolic process | 2.754E-05 | 9.363E-03 | ACHE, BCHE, CYP1A1, CYP1B1, CYP2C19, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 2.838E-05 | 9.363E-03 | BCHE, CYP3A4 |
| BP | GO:0032502; developmental process | GO:0045766; positive regulation of angiogenesis | 3.057E-05 | 9.937E-03 | CYP1B1, HIF1A, PRKCA, PTGS2 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 2.586E-09 | 3.517E-07 | HSD17B1; CYP1A1; CYP1B1; PTGS2; CYP19A1 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 5.559E-09 | 3.780E-07 | HSD17B1; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 3.251E-08 | 1.474E-06 | CYP1A1; CYP1B1; CYP3A4; CYP2C19; PTGS2 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 7.601E-06 | 2.067E-04 | MAPK1; PRKCA; CYP2C19; PTGS2 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 4.356E-05 | 8.893E-04 | MAPK1; PRKCA; HIF1A |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 7.529E-05 | 1.066E-03 | KIT; MAPK1; PRKCA; PTGS2; HIF1A |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 4.578E-05 | 8.893E-04 | MAPK1; PRKCA; PTGS2 |
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 8.939E-07 | 3.039E-05 | CA12; CA4; CA7 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 6.066E-05 | 1.031E-03 | KIT; MAPK1; HIF1A |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 7.840E-05 | 1.066E-03 | CYP1A1; CYP1B1; CYP3A4 |
| hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 1.997E-04 | 2.117E-03 | KIT; MAPK1; PRKCA |
| hsa04723 | Retrograde endocannabinoid signaling_Homo sapiens_hsa04723 | 2.057E-04 | 2.117E-03 | MAPK1; PRKCA; PTGS2 |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 2.717E-04 | 2.464E-03 | ACHE; MAPK1; PRKCA |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 2.057E-04 | 2.117E-03 | MAPK1; PRKCA; HIF1A |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 2.180E-04 | 2.117E-03 | MAPK1; PRKCA; HIF1A |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 3.502E-04 | 2.507E-03 | GAA; HSD17B1; CYP1A1; PTGS2; CYP2C19; CYP3A4; CYP19A1 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 3.377E-04 | 2.507E-03 | CYP1B1; MAPK1; PRKCA; PTGS2 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 3.253E-04 | 2.507E-03 | MAPK1; PRKCA; HIF1A |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 3.417E-04 | 2.507E-03 | OPRD1; MAPK1; PRKCA |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 5.825E-04 | 3.772E-03 | KIT; MAPK1; PRKCA |
| hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 7.628E-04 | 4.715E-03 | MAPK1; PRKCA; PTGS2 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.571E-03 | 8.545E-03 | MAPK1; PRKCA; HIF1A |
| hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 1.754E-03 | 9.111E-03 | KIT; MAPK1; PRKCA |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 2.161E-03 | 9.479E-03 | KIT; MAPK1; PRKCA |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 1.876E-03 | 9.111E-03 | MAPK1; PRKCA |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.876E-03 | 9.111E-03 | PTGS2; TSHR |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.943E-03 | 9.111E-03 | KIT; MAPK1 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 2.518E-03 | 9.803E-03 | MAPK1; PRKCA |
| hsa04730 | Long-term depression_Homo sapiens_hsa04730 | 2.150E-03 | 9.479E-03 | MAPK1; PRKCA |
| hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 9.135E-04 | 5.401E-03 | MAPK1; PRKCA |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 9.609E-04 | 5.445E-03 | CYP1A1; CYP1B1 |
| hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 2.752E-03 | 1.011E-02 | MAPK1; PRKCA |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 6.756E-03 | 1.955E-02 | KIT; MAPK1; PRKCA |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 2.294E-03 | 9.749E-03 | CYP2C19; PTGS2 |
| hsa04720 | Long-term potentiation_Homo sapiens_hsa04720 | 2.595E-03 | 9.803E-03 | MAPK1; PRKCA |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 5.962E-03 | 1.763E-02 | MAPK1; PRKCA |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 2.595E-03 | 9.803E-03 | MAPK1; HIF1A |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 4.460E-03 | 1.477E-02 | MAPK1; PRKCA |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 2.518E-03 | 9.803E-03 | CYP1A1; CYP3A4 |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 4.868E-03 | 1.540E-02 | MAPK1; PRKCA |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 5.040E-04 | 3.427E-03 | CYP3A4; CYP2C19 |
| hsa04713 | Circadian entrainment_Homo sapiens_hsa04713 | 5.293E-03 | 1.600E-02 | MAPK1; PRKCA |
| hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 5.079E-03 | 1.570E-02 | MAPK1; PRKCA |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 3.164E-03 | 1.076E-02 | MAPK1; PTGS2 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 2.832E-03 | 1.014E-02 | CYP3A4; CYP2C19 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 7.033E-03 | 1.993E-02 | MAPK1; PTGS2 |
| hsa04918 | Thyroid hormone synthesis_Homo sapiens_hsa04918 | 2.996E-03 | 1.045E-02 | PRKCA; TSHR |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 4.560E-03 | 1.477E-02 | MAPK1; PRKCA |
| hsa04724 | Glutamatergic synapse_Homo sapiens_hsa04724 | 7.535E-03 | 2.091E-02 | MAPK1; PRKCA |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.211E-02 | 3.108E-02 | MAPK1; PRKCA |
| hsa04270 | Vascular smooth muscle contraction_Homo sapiens_hsa04270 | 8.318E-03 | 2.263E-02 | MAPK1; PRKCA |
| hsa04650 | Natural killer cell mediated cytotoxicity_Homo sapiens_hsa04650 | 1.043E-02 | 2.727E-02 | MAPK1; PRKCA |
| hsa04142 | Lysosome_Homo sapiens_hsa04142 | 8.723E-03 | 2.326E-02 | NPC1; GAA |
| hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 1.243E-02 | 3.130E-02 | MAPK1; PRKCA |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 1.563E-02 | 3.865E-02 | OPRD1; MAPK1 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 1.707E-02 | 4.146E-02 | MAPK1; PRKCA |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; MAPK1; KIT; ACHE; PTGS2 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | PTGS2 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PTGS2 |
| K00-K95: Diseases of the digestive system | Diarrhea-predominant IBS | K58.0 | OPRD1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | KIT; PTGS2 |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | OPRD1 |
| NA: NA | Joint and muscular pain | NA | PTGS2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE |
| NA: NA | Chronic diarrhea associated with inflammatory bowel disease | NA | OPRD1 |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | OPRD1; ACHE; PTGS2; PTGS2; PTGS2; PTGS2 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Moderate-to-severe pain | R52, G89 | OPRD1 |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PTGS2 |
| NA: NA | Rheumatold arthritis | NA | PTGS2; PTGS2; PTGS2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; PTGS2 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; MAPK1; KIT |
| G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | OPRD1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | OPRD1; CYP3A4; ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; ACHE; ACHE; PTGS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS2; PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | OPRD1 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTGS2 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS2; PTGS2; PTGS2; PTGS2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | OPRD1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | OPRD1 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | OPRD1 |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PTGS2 |
| N00-N99: Diseases of the genitourinary system | Bladder disease | N30-N32 | OPRD1 |
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1 |
| I00-I99: Diseases of the circulatory system | Ischemic heart diseases | I20-I25 | OPRD1 |
| NA: NA | Acute nonspecific diarrhea | NA | OPRD1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | OPRD1; PTGS2; PTGS2; PTGS2; PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | OPRD1 |